We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ContraFect Corp (CFRX) USD0.0001

Sell:$3.34 Buy:$3.40 Change: $0.19 (5.90%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.19 (5.90%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Change: $0.19 (5.90%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infection. Its lead DLA candidate includes exebacase, which is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia, and osteomyelitis. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. The Company is conducting Phase II clinical study of exebacase for the treatment of Staph aureus bacteremia, including right-sided endocarditis, caused by MRSA or MSSA.

Contact details

28 Wells Ave Ste 3
United States
+1 (914) 2072300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$126.65 million
Shares in issue:
39.33 million
United States
US dollar

Key personnel

  • Roger Pomerantz
    Chairman of the Board, President, Chief Executive Officer
  • Steven Gilman
    Vice Chairman of the Board
  • Michael Messinger
    Chief Financial Officer
  • Cara Cassino
    Executive Vice President - Research and Development, Chief Medical Officer
  • Gary Woodnutt
    Senior Vice President - Translational Sciences and Preclinical Development
  • Natalie Bogdanos
    General Counsel, Corporate Secretary , Data Protection Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.